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Abstract: Hierridin B (6), a methylated hydroquinone isolated from the marine picocyanobacterium 
Cyanobium sp. LEGE 06113, moderately inhibited the growth of colon adenocarcinoma HT-29 cells. 
Aiming to improve the potential antitumor activity of this natural product, the demethylated 
analogue, norhierridin B (10), as well as its structurally-related quinone (9), were synthesized and 
evaluated for their growth inhibitory effect on a panel of human tumor cell lines, including the 
triple-negative breast cancer (TNBC) cells MDA-MB-231, SKBR3, and MDA-MB-468. Norhierridin 
B (10) showed a potent growth inhibitory effect on all cancer cell lines. Moreover, the growth 
inhibitory effect of compound 10 on MDA-MB-231 cells was associated with cell cycle arrest and 
apoptosis. Norhierridin B (10) interfered with several p53 transcriptional targets, increasing p21, 
Bax, and MDM2, while decreasing Bcl-2 protein levels, which suggested the potential activation of 
a p53 pathway. Altogether, these results evidenced a great improvement of the antitumor activity 
of hydroquinone 10 when compared to 6 and its structurally-related quinone (9). Notably, 
hydroquinone 10 displayed a prominent growth inhibitory activity against TNBC cells, which are 
characterized by high therapeutic resistance. 
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1. Introduction 
Quinones/hydroquinones constitute a family of metabolites, widespread in nature, with a wide 
range of biological activities, including cytotoxicity to cancer cells [1–3]. Particularly, alkyl 1,4-
benzoquinones/hydroquinones with aliphatic side chains have been found attractive for their in vitro 
growth inhibitory effect against several human cancer cell lines [3,4] (Figure 1). Among these 
secondary metabolites, a wide array of bioactive compounds has been isolated from nature, namely 
from plant species and marine organisms. For instance, compounds 1–3 (Figure 1), isolated from 
Ardisia virens, exhibited a potent inhibitory effect against breast adenocarcinoma MCF-7, non-small 
cell lung cancer NCI-H460, and glioblastoma SF-268 cell lines (concentration that caused cell growth 
inhibition of 50%, GI50, of 2.21–11.32 µM) [4], with hydroquinone 3 being more potent than quinone 
2. Toluquinol (4) (Figure 1), isolated from the marine fungus Penicillium sp. HL-85-ALS5-R004, is 
another example of a natural product with a promising in vitro growth inhibitory effect in breast 
adenocarcinoma MDA-MB-231 and glioblastoma U87-MG cells, as well as in promyelocytic leukemia 
HL-60, fibrosarcoma HT-1080, and colorectal adenocarcinoma HT-29 cell lines [5]. Interestingly, 
when comparing the in vitro growth inhibitory activity of quinones with structurally related 
hydroquinones, it seems that the presence of a hydroquinone could be more favorable for activity. In 
fact, the IC50 values obtained for quinone 2 are slightly higher than those of the structurally related 
hydroquinone 3 [4]. Moreover, toluquinone (5), a synthetic analogue of the marine hydroquinone 
toluquinol (4), showed lower in vitro growth inhibitory activity against a panel of cancer cell lines of 
breast adenocarcinoma (MDA-MB-231, GI50 of 3.4 ± 0.1 µM), promyelocytic leukemia (HL-60, GI50 of 
5.6 ± 1.9 µM), glioblastoma (U87-MG, GI50 of 8.8 ± 0.9 µM), fibrosarcoma (HT-1080, GI50 of 4.9 ± 1.7 
µM), and colorectal adenocarcinoma (HT-29, GI50 of 9.5 ± 0.5 µM) than toluquinol (5) (MDA-MB-231: 
GI50 of 2.3 ± 0.8 µM, HL-60: GI50 of 1.7 ± 0.5 µM, U87-MG: GI50 of 5.6 ± 1.5 µM, HT-1080: GI50 of 1.4 ± 
0.6 µM and HT-29: GI50 of 4.1 ± 0.4 µM), further supporting that the presence of a hydroquinone is 
favorable for the antitumor activity [5]. 
 
Figure 1. Structure of quinones and hydroquinones with cytotoxic activity. 
Recently, following the search for new bioactive secondary metabolites from marine 
cyanobacteria, we identified hierridin B (6), a methylated hydroquinone derivative with a C15 
aliphatic chain isolated from the marine picocyanobacterium Cyanobium sp. LEGE 06,113 [6]. 
Compound 6 moderately inhibited the growth of colon adenocarcinoma HT-29 cell line, with a GI50 
of 100.2 µM [6]. In order to obtain new structurally-related quinone/hydroquinone with improved 
antiproliferative activity in cancer cell lines, the demethylated hierridin B derivative, norhierridin B 
(10), as well as structurally-related quinone 9 and compound 6, were synthesized and evaluated for 
their growth inhibitory effect in a panel of human tumor cell lines. 
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2. Results and Discussion 
2.1. Synthesis 
Norhierridin B (10) was synthesized according to the strategy illustrated on Scheme 1. In order 
to explore the growth inhibitory effect of demethylated hierridin B (6) derivative (10), as well as of its 
1,4-benzoquinone analogue (9), a synthetic pathway was planned in order to obtain this analogue as 
an intermediate. Firstly, Grignard addition to o-vanilin using tetradecyl magnesium bromide in situ 
prepared from Mg turnings and tetradecyl bromide in dry diethyl ether afforded the corresponding 
carbinol 7 with 14% yield. The reduction of α-hydroxy group was firstly attempted by hydrogenolysis 
catalyzed by palladium on carbon (Pd/C) using sulfuric acid as hydrogen donor, as reported by 
González et al. [7]. Nevertheless, as no reaction occurred, a similar reaction with Pd/C using formic 
acid as hydrogen donor was conducted, affording the reduced derivative 8 with 93% yield. The high 
yield obtained reinforces the advantage of using palladium catalysts and formic acid in the catalytic 
transfer hydrogenolysis of benzylic alcohols, as described previously [8–10]. Phenol 8 was oxidized 
by streaming oxygen into a solution of DMF containing salcomine as catalyst, affording the 1,4-
benzoquinone 9 with good yield (82%). The reduction of quinone 9 using Na2S2O4 as a reducing agent 
afforded norhierridin B (10) with 87% yield. 
The structure elucidation of the new hydroquinone 10 was established by NMR and HRMS 
(Figures S4 and S5). The newly synthesized quinone 9, as well as intermediates 7 and 8, were 
characterized by NMR techniques, and data were in accordance with that previously reported [11,12]. 
13C-NMR assignments were determined by 2D heteronuclear single quantum correlation (HSQC) and 
heteronuclear multiple bond correlation (HMBC) experiments. Hierridin B (6) was synthesized and 
characterized as described previously [13]. 
 
Scheme 1. Synthesis of norhierridin B (10). (a) C14H29Br, Mg, Et2O, 35 °C, 2 h; (b) HCOOH, Pd/C, 
EtOH/H2O, 80 °C, 4 h; (c) O2, salcomine, DMF, r. t., 24 h; (d) Na2S2O4, CHCl3/H2O, r.t., 10 min. 
2.2. Biological Activity 
Tumor Cell Growth Inhibitory Activity Evaluation 
The growth inhibitory effect of norhierridin B (10), as well as of its structurally related 1,4-
benzoquinone (9), intermediates 7 and 8, and hierridin B (6), was evaluated in a panel of distinct 
human cancer cell lines of melanoma (A375), hepatocarcinoma (Huh-7), colon (HCT116), and triple-
negative breast cancer (TNBC) (MDA-MB-231, SKBR3, and MDA-MB-468), using the sulforhodamine 
(SRB) assay. A dose-response curve was obtained for each compound in the distinct cell lines and the 
concentration that induced half of growth inhibition (GI50) was determined after 48 h treatment (Table 
1). 
Molecules 2020, 25, 1578 4 of 10 
 
Table 1. Effect of compounds 6–10 on the growth of human cancer cell lines. 
 GI50 (μM)  
Cell line/Compound 6 7 8 9 10 Etoposide 
MDA-MB-231 >50 9.65 ± 0.15 28.8 ± 3.3 5.83 ± 1.10 0.61 ± 0.07 5.06 ± 1.24 
SKBR3 >50 14.0 ± 0.0 >50 4.35 ± 0.15 0.77 ± 0.06 4.77 ± 1.09 
MDA-MB-468 >50 7.85 ± 2.15 31.00 ± 7.00 6.65 ± 0.90 0.68 ± 0.13 2.14 ± 0.36 
A375 >50 16.0 ± 1.7 32.9 ± 4.2 20.6 ± 1.9 2.0 ± 0.4 0.9 ± 0.07 
Huh-7 >50 27.5 ± 0.5 >50 2.95 ± 0.15 0.61 ± 0.03 3.43 ± 0.85 
HCT116 >50 26.5 ± 0.5 26.0 ± 3.2 29.6 ± 0.5 3.2 ± 0.6 0.67 ± 0.05 
GI50 was determined by sulforhodamine (SRB) assay after 48 h treatment (growth obtained with 
vehicle was set as 100%). Data are mean ± SEM of two to five independent experiments. Etoposide 
was used as positive control. 
The obtained GI50 values revealed that all newly synthesized compounds (7, 8, 9, and 10) had a 
much higher growth inhibitory activity than hierridin B (6) in all cancer cell lines (Table 1). 
Norhierridin B (10) was found to be the most effective against all cancer cell lines, exhibiting much 
lower GI50 values than its methyl derivative hierridin B (6). These results suggest that the presence of 
two p-hydroxy groups in the hydroquinone scaffold are important for the in vitro growth inhibitory 
activity. In addition, norhierridin B (10) displayed higher activity than its structurally related quinone 
(9), reinforcing that the presence of a hydroquinone scaffold is more favorable for the activity than a 
quinone scaffold, as already reported by Chang et al. [4] and Cheng-Sánchez et al. [5] for other 
structurally related hydroquinones/quinones. 
Interestingly, norhierridin B (10) exhibited a prominent growth inhibitory activity against TNBC 
cells MDA-MB-231, SKBR3, and MDA-MB-468, which are well-known by their high therapeutic 
resistance [14]. Moreover, an evident reduction of the norhierridin B (10) antiproliferative effect could 
be observed by SRB assay in non-tumorigenic MCF10A breast epithelial cell lines (10.36 ± 1.96 µM, 
three independent experiments). In fact, supporting the marked antiproliferative effect of compound 
10 on MDA-MB-231 cells, observed by SRB assay (Figure 2A), a pronounced inhibition of the growth 
of these cancer cells was also observed at 2 µM by colony formation assay (Figure 2B,2C). 
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Figure 2. Norhierridin B (10) inhibits the growth of breast adenocarcinoma MDA-MB-231 cells. (A) 
Dose-response curve for the growth of MDA-MB-231 cells treated with compound 10 for 48 h, 
determined by SRB assay; data are mean ± SEM of four independent experiments; growth obtained 
with vehicle was set as 100%. (B, C) Colony formation assay for MDA-MB-231 cells treated with 
compound 10 for nine days: (B) images correspond to a representative experiment of two; (C) graph 
represents mean ± SEM of two independent experiments; values significantly different from DMSO: 
*** p < 0.001, unpaired Student’s t-test. 
It was also verified that the growth inhibitory effect of compound 10 on MDA-MB-231 cells was 
associated with the induction of apoptosis and cell cycle arrest. In fact, the 1 µM concentration of 
compound 10 caused a significant G0/G1-phase cell cycle arrest (Figure 3A), which was consistent 
with the visible increase of p21 protein expression levels observed by western blot analysis (Figure 
3C). Moreover, by cell viability assay, 1 and 2 µM of compound 10 significantly increased the 
percentage of dead cells (Figure 3B), which was associated with an increase of the pro-apoptotic 
protein Bax and a decrease of the anti-apoptotic protein Bcl-2 (Figure 3C). It is interesting to note that 
compound 10 interfered with the protein expression levels of several p53 transcriptional targets, such 
as p21, Bax, Bcl-2, and MDM2 (Figure 3C), suggesting the activation of a p53 pathway in MDA-MB-
231 cells. Collectively, these results indicate that compound 10 is very effective against TNBC cells. 
The poor prognosis and limited therapeutic options commonly observed with this type of cancer [14] 
render compound 10 worthy of further studies to confirm its promising application as potential 
anticancer agent, particularly against TNBC. 
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Figure 3. Norhierridin B (10) induces cell cycle arrest and death and interferes with p53 transcriptional 
targets. (A) Cell cycle progression was analyzed after 48 h treatment with compound 10 in MDA-MB-
231 cells; data are mean ± SEM of three independent experiments; values significantly different from 
DMSO: *p < 0.05, unpaired Student’s t-test. (B) Percentage of death cells determined by trypan blue 
assay for MDA-MB-231 cells treated with compound 10 for 48 h; data are mean ± SEM of three 
independent experiments; values significantly different from DMSO: *p < 0.05, **p < 0.001, unpaired 
Student’s t-test. (C) Protein expression levels of p53 targets in MDA-MB-231 cells was analyzed by 
western blot after 48 h treatment with 2 µM compound 10. Immunoblots are representative of three 
independent experiments; GAPDH was used as loading control. 
3. Material and Methods 
3.1. Synthesis 
All reactions were monitored by thin-layer chromatography (TLC). Purifications of compounds 
were carried out by flash chromatography using Macherey-Nagel silica gel 60 (0.04–0.063 mm). 
Melting points were obtained in a Köfler microscope (Wagner and Munz, Munich, Germany) and are 
uncorrected. 1H-NMR and 13C-NMR spectra were taken in CDCl3 at room temperature, on a Bruker 
Avance 300 instrument (300.13 MHz for 1H and 75.47 MHz for 13C, Bruker Biosciences Corporation, 
Billerica, MA, USA). Chemical shifts are expressed in ppm values relative to tetramethylsilane (TMS) 
used as an internal reference; 13C-NMR assignments were made by 2D (HSQC and HMBC) NMR 
experiments (long-range 13C-1H coupling constants were optimized to 7 Hz). HRMS mass spectrum 
was recorded as ESI (electrospray ionization) mode on a MicrOTOF spectrometer (Bruker 
Corporation, Billerica, MA, USA) at C.A.C.T.I.-University of Vigo, Spain. The commercially available 
reagents, and etoposide, were purchased from Sigma Aldrich Co. (Sintra, Portugal). Reagents and 
solvents were purified and dried according to the usual procedures described elsewhere [15]. 
Hierridin B (6) was synthesized as described previously [13]. The following materials were 
synthesized and purified by the described procedures. 
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3.1.1. Synthesis of 2-(1-hydroxypentadecyl)-6-methoxyphenol (7) 
Tetradecyl magnesium bromide was prepared from Mg turnings (2.01 g, 0.62 eq.) and tetradecyl 
bromide (37 g, 0.13 mol) in dry diethyl ether (200 mL) under a nitrogen atmosphere. o-Vanilin (10 g, 
0.066 mol) was gradually added, and the mixture was then refluxed for 2 h, cooled, and poured into 
a saturated solution of NH4Cl (150 mL). The layers were separated, and the aqueous phase 
thoroughly extracted with diethyl ether (3 × 200 mL). The organic layer was washed with water, dried 
over anhydrous sodium sulfate, and evaporated under reduced pressure. The residue was purified 
by flash column chromatography (silica gel, n-hexane: ethyl acetate 8:2), affording 7 (3.23 g, 14%) as 
a white solid. 
2-(1-hydroxypentadecyl)-6-methoxyphenol (7): 1H-NMR (CDCl3, 300.13 MHz): δ = 6.83–6.78 (m, 3H, H-
3,-4,-5), 6.38 (s, 1H, 1-OH), 4.87 (t, J = 6.0 Hz, 1H, H-1′), 3.88 (s, 3H, 2-OCH3), 1.84–1.80 (m, 2H, H-2′), 
1.30–1.24 (m, 24 H, H-3′-14′), 0.87 (t, J = 6.5 Hz, 3H, H-15′); 13C-NMR (CDCl3, 75.47 MHz) δ: 146.8 (C-
2), 143.1 (C-1), 129.8 (C-6), 119.6 (C-4), 119.2 (C-5), 109.7 (C-3), 72.0 (C-1′), 56.0 (2-OCH3), 37.2 (C-2′), 
31.9–22.7 (C-2′-14′), 14.1 (C-15′). 
3.1.2. Synthesis of 2-methoxy-6-pentadecylphenol (8) 
In a 250 mL two neck round-bottomed flask equipped with a water-cooled condenser and a 
magnetic stirrer, ethanol (99 mL), water (20 mL), compound 7 (3.17 g, 9 mmol), formic acid (0.68 mL), 
and Pd/C 10% (w/w) (1.259 g) were added. The reactor was placed in a preheated oil bath and 
maintained at 80 °C under atmospheric pressure for 4 h. The reactor was allowed to cool down to r.t., 
and the ethanol was evaporated under reduced pressure. Water was added (20 mL), and the resulting 
solution was extracted with diethyl ether (3 × 100 mL). The organic layer was dried over anhydrous 
sodium sulfate and evaporated under reduced pressure affording a solid, which was crystallized 
from diethyl ether: methanol affording the title compound (8) (2,81 g, 93%) as a white solid. 
2-methoxy-6-pentadecylphenol (8): 1H-NMR (CDCl3, 300.13 MHz): δ = 6.80–6.70 (m, 3H, H-3,-4,-5), 5.66 
(s, 1H, 1-OH), 3.87 (s, 3H, 2-OCH3), 2.62 (t, J = 7.6 Hz, 1H, H-1′), 1.65–1.57 (m, 2H, H-2′), 1.27–1.25 (m, 
24 H, H-3′-14′), 0.87 (t, J = 6.5 Hz, 3H, H-15′); 13C-NMR (CDCl3, 75.47 MHz) δ: 146.3 (C-2), 143.4 (C-1), 
128.8 (C-6), 122.3 (C-5), 119.1 (C-4), 108.1 (C-3), 55.9 (2-OCH3), 31.9 (C-2′), 30.9 (C-1′), 37.2 (C-2′), 29.8–
22.7 (C-2′-14′), 14.1 (C-15′). 
3.1.3. Synthesis of 2-methoxy-6-pentadecyl-1,4-benzoquinone (9) 
A solution of 8 (2.17 g, 6 mmol) in DMF was bubbled with O2 for 5 min and, after the O2 
atmosphere, was kept over the reaction vessel. Salcomine was added (380 mg, 1.17 mmol), and the 
reaction was stirred at r.t. for 24 h. After, diethyl ether (20 mL) was added, and the organic layer was 
washed with 0.1 M HCl (2 × 10 mL), water (10 mL) and brine (10 mL). The organic layer was dried 
over anhydrous sodium sulfate, and the solvent evaporated. The obtained solid was purified by 
crystallization from petroleum ether 40–60 °C, affording the title compound (9) (1.85 g, 82%) as a 
yellow solid. 
2-methoxy-6-pentadecyl-1,4-benzoquinone (9): 1H-NMR (CDCl3, 300.13 MHz): δ = 6.49–6.47 (m, 1H, H-5), 
5.87 (d, J = 2.4 Hz, 1H, H-3), 3.82 (s, 3H, 2-OCH3), 2.44 (ddd, J = 7.5 Hz, 1.4, 2H, H-1′), 1.54–1.45 (m, 
2H, H-2′), 1.30–1.25 (m, 24 H, H-3′-14′), 0.88 (t, J= 6.5, 3H, H-15′); 13C-NMR (CDCl3, 75.47 MHz) δ: 187.7 
(4-CO), 182.2 (1-CO), 158.9 (C-2), 147.6 (C-6), 132.9 (C-5), 107.1 (C-3), 55.3 (2-OCH3), 28.7 (C-1′), 27.7 
(C-2′), 29.8–22.7 (C-2′-14′), 14.1 (C-15′). 
3.1.4. Synthesis of 2-methoxy-6-pentadecylbenzene-1,4-diol (10). 
Compound 9 (1.86 g, 0.005 mol) was dissolved in chloroform and added to a 10% solution of 
Na2S2O4 in hot water. The mixture was shaken for 10 min, and, after the aqueous layer was drawn 
off, the chloroform was shaken with brine, dried over anhydrous sodium sulfate, and the solvent 
evaporated under reduced pressure. The residue was purified by crystallization from n-hexane, 
affording the title compound (10) (1.31 g, 87%) as a white solid. 
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2-methoxy-6-pentadecylbenzene-1,4-diol (10): m.p. (n-hexane) = 92–94 °C; 1H-NMR (CDCl3, 300.13 MHz): 
1H-NMR (CDCl3, 300.13 MHz): δ 6.31 (d, J = 2.8 Hz, 1H, H-3), 6.20 (d, J = 2.8 Hz, 1H, H-5), 3.84 (s, 3H, 
2-OCH3), 2.56 (t, J = 7.5 Hz, 2H, H-1′), 1.60–1.52 (m, 2H, H-2′), 1.30–1.25 (m, 24H, H-3′-14′), 0.87 (t, J = 
6.5 Hz, 3H, H-15′); 13C-NMR (CDCl3, 75.47 MHz): δ 148.3 (C-2), 147.6 (C-4), 137.3 (C-1), 107.9 (C-5), 
97.0 (C-3), 56.3 (2-OCH3), 31.9 (C-2′), 30.9 (C-1′), 29.8–22.7 (C-2′-14′), 14.1 (C-15′); ESI-TOF-HRMS (+) 
m/z: Anal. Calc. for C24H37O3 (M+H+): 349.27320; found: 349.27372. 
3.2. Biological Activity 
3.2.1. Human Cell Lines and Growth Conditions 
Human breast adenocarcinoma MDA-MB-231, SK-BR-3, MDA-MB-468, melanoma A375, 
hepatocellular carcinoma Huh-7, colorectal carcinoma HCT116, and non-tumorigenic breast 
epithelial MCF10A cell lines were purchased from ATCC (Rockville, MD, USA). Cancer cells were 
cultured in RPMI-1640 medium with UltraGlutamine (Biowest, VWR, Carnaxide, Portugal) with 10% 
fetal bovine serum (FBS; Gibco, Alfagene, Lisboa, Portugal). MCF10a cells were cultured in 
DMEM:F12 with 10% FBS or MEGM SingleQuot Kit Suppl. & Growth Factors, respectively (Lonza, 
VWR, Carnaxide, Portugal). Cells were maintained at 37 °C in a humidified atmosphere of 5% CO2. 
Mycoplasma detection was routinely performed using the MycoAlert™ PLUS kit (Lonza). 
3.2.2. Sulforhodamine B (SRB) Assay 
Human cell lines were incubated in 96-well plates at a final density of 5.0 × 103 cells/well (for 
A375, Huh-7 and HCT116 cells), 1.0 × 104 cells/well (for MDA-MB-231 and MCF10A) and 7.5 × 103 
cells/well (for SKBR3 and MDA-MB-468 cells) for 24 h. Cells were then treated with serial dilutions 
(0.313 µM to 50 µM) of compounds for 48 h. The effect of these compounds on in vitro growth was 
assessed using the SRB assay. Cells were fixated with 12.5% TCA for 1 h at 4 °C. Plates were then 
stained with 0.25% SRB (Sigma-Aldrich, Sintra, Portugal) and washed with 1% acetic acid. The bound 
dye was solubilized in 0.12% Tris Base and the absorbance was measured at 510 nm in a microplate 
reader (Biotek Instruments Inc., Synergy, MX, USA). The maximum concentration of solvent used in 
this assay (1% DMSO) was included as control. The GI50 was then determined. 
3.2.3. Colony Formation Assay 
MDA-MB-231 cells were seeded in 6-well plates at a density of 5.0 × 102 cells/well, followed by 
incubation with hydroquinone 10 for 9 days. Formed colonies were fixed with 10% MeOH and 10% 
AcOH for 10 min, and then they were stained with 0.5% crystal violet (Sigma-Aldrich, Sintra, 
Portugal) in 1:1 MeOH/H2O for 15 min. Colonies containing more than 20 cells were counted. 
3.2.4. Cell Viability Assay 
The percentage of viable cells was determined using the Trypan Blue Assay. Briefly, MDA-MB-
231 cells were seeded in 24-well plates at 6 × 104 cells/well for 24 h, followed by treatment with 
hydroquinone 10 for 24 h. Cells were then harvested and resuspended in 0.4% Trypan Blue (Sigma-
Aldrich, Sintra, Portugal), and the number of viable/dead cells were counted using a Leica light 
optical microscope (Wetzlar). Vehicle (0.25% DMSO) was included as a control. 
3.2.5. Cell Cycle Analysis 
Cell cycle and apoptosis were analyzed as described [16]. Briefly, MDA-MB-231 cells were 
incubated in 6-well plates at a density of 2.25 × 105 cells/well for 24 h. Cells were then treated with 
hydroquinone 10 or DMSO only for 48 h. For cell cycle analysis, cells were stained with propidium 
iodide (PI; Sigma-Aldrich, Sintra, Portugal); cell cycle scattering was analyzed by flow cytometry and 
cell cycle phases were quantified using FlowJoX v10.0.7 (Treestar, Woodburn, OR, USA). 
3.2.6. Western Blot Analysis 
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MDA-MB-231 cells were seeded in 6-well plates at a density of 2.25 × 105 cells/well for 24 h, 
followed by treatment with 2 µM hydroquinone 10. Protein extracts were quantified using the 
Bradford reagent (Sigma-Aldrich, Sintra, Portugal). Proteins were run in SDS-PAGE and transferred 
to a Whatman nitrocellulose membrane from Protan (VWR, Carnaxide, Portugal). After blocking, 
proteins were identified using a mouse monoclonal anti-anti-MDM2 (D-12), anti-Bax (2D2), anti-Bcl-
2 (C-2), or a rabbit polyclonal anti-p21 (C-19), followed by an anti-mouse or anti-rabbit horseradish-
peroxidase (HRP)-conjugated secondary antibody. For the loading control, a mouse monoclonal anti-
GAPDH (6C5) was used. The signal was detected with the ECL Amersham kit from GE Healthcare 
(VWR, Carnaxide, Portugal). The ChemiDoc™ XRS Imaging System from Bio-Rad Laboratories 
(Amadora, Portugal) for Microsoft Windows 10 was used for detection. 
3.2.7. Statistical analysis 
Data were statistically analyzed using GraphPad Prism version 7.0. Different statistical tests 
were used accordingly to the dataset; p values  <0.05 or < 0.001 were considered statistically 
significant. 
4. Conclusions 
In this work, the demethylated derivative of hierridin B (6) and norhieridin B (10), as well as its 
structurally related quinone (9), were synthesized for the first time. The study of their effect on the in 
vitro cell growth inhibition of human tumor cell lines revealed that norhierridin B (10) was the most 
effective in all cancer cell lines, exhibiting much lower IC50 values than its structurally related quinone 
(9) and hierridin B (6). Particularly, hydroquinone 10 exhibited a noticeable growth inhibitory activity 
against the TNBC cells MDA-MB-231, SKBR3, and MDA-MB-468, with these being effects associated 
with cell cycle arrest; increase of p21 and Bax; and decrease of Bcl-2 protein expression levels. The 
interference of hydroquinone 10 in MDA-MB-231 cells with the protein expression levels of the p53 
transcriptional targets p21, Bax, Bcl-2, and MDM2 suggests the activation of a p53 pathway, which 
should be further explored in the future. Altogether, these results indicate that hydroquinone 10 
could be an effective cytotoxic agent against TNBC cells, which should be further explored in the 
future. 
Supplementary Materials: The following are available online, Figure S1: 1H and 13C-NMR of compound 7, 
Figure S2: 1H and 13C-NMR of compound 8, Figure S3: 1H and 13C-NMR of compound 9, Figure S4: 1H and 13C-
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